Skip to content

H03 — siRNA / URAT1 Discovery-Engine Output Thesis (Stub)

Stub status. This card is committed at stub-level on 2026-05-05 to register the hypothesis in the falsification-card directory and force the "what would kill this thesis" framing onto the siRNA / URAT1 page. Full population (assumption stack, killshot menu, pre-committed thresholds, kill switches, failure-mode coverage map) is queued as Phase 2 P2-5 — see sirna-urat1-modality.md § Open Follow-Ups.

The pre-registration note on H01 (H01-ward-dual-cassette.md §Pre-registration) does not apply until this stub is upgraded to a full card. When the upgrade happens, the upgraded version is what gets pre-registered; the stub is informational scaffolding only.

Claim (provisional, stub-level)

A kidney-tropic siRNA conjugate targeting URAT1 (SLC22A12) mRNA is a viable long-horizon therapeutic modality for under-excreter gout, with three distinguishing advantages over the existing small-molecule URAT1 inhibitor class (probenecid, lesinurad, dotinurad, pozdeutinurad / AR882):

  1. Sequence-specificity eliminates the off-target metabolite class — categorically different safety profile than benzbromarone-class chemistry, where reactive metabolites caused fulminant hepatotoxicity and market withdrawal
  2. Durability — single-dose effect persisting weeks to months (per inclisiran's ~6-month PCSK9 silencing precedent), shifting from daily-pill compliance to quarterly subcutaneous injection
  3. Hormone-independence — siRNA knockdown is not subject to androgen-axis modulation of URAT1 expression, working as effectively in clomid / TRT / endogenous-T-elevated patients (where URAT1 is upregulated) as in baseline patients

The thesis is gated on the maturation of kidney-tropic conjugate delivery chemistry — none of the four current research-class approaches (megalin-binding peptide conjugates, CDP nanoparticles, kidney-cortex-selective LNPs, aptamer-siRNA chimeras) has reached first-in-human for any indication. The "viable" claim is therefore conditional: viable if kidney-tropic delivery chemistry converges within 3–5 years; deferred indefinitely if it does not.

This vector is positioned as a discovery-engine output (per open-enzyme-vision.md §2.2), not a strain-library output. The thesis is that Open Enzyme contributes mechanistic clarity, target validation, and design rationale — partner companies, academic groups, or future spinouts execute the development.

Assumption Stack (placeholder — to be populated in Phase 2 P2-5)

The full assumption stack will be populated after the four Phase 2 lit scans (P2-1 conjugate chemistry, P2-3 commercial landscape, P2-4 competitive analysis vs. small-molecule URAT1 inhibitors, P2-6 FDA siRNA regulatory path) and comp-009 (P2-2 URAT1 mRNA target site selection) land. Anticipated load-bearing assumptions, to be confirmed:

  1. URAT1 mRNA has accessible target sites with sufficient secondary-structure exposure for effective siRNA design (verified by comp-009)
  2. Kidney-tropic conjugate chemistry reaches first-in-human within 3–5 years for at least one indication (Alport syndrome, polycystic kidney disease, etc., not necessarily gout)
  3. Megalin-mediated proximal tubule uptake achieves siRNA delivery efficiency at therapeutically meaningful levels (target: ≥50% knockdown of URAT1 protein at well-tolerated dose)
  4. The 6-month durability inclisiran demonstrates for liver-targeted siRNA generalizes to kidney-tropic siRNA (proximal tubule cell turnover is ~6–12 months in healthy kidney; durability should be similar or longer)
  5. ~50% URAT1 knockdown produces clinically-meaningful uric acid reduction (analog: lesinurad at 200 mg/day produces ~1.1 mg/dL UA reduction per published trials; siRNA-mediated knockdown should produce comparable or larger effect)
  6. The 5–10 year competitive horizon vs. pozdeutinurad and post-pozdeutinurad small-molecule URAT1 modulators preserves a meaningful therapeutic niche (durability, safety, hormone-independence advantages outweigh the small-molecule class's earlier launch and lower cost)

Killshot Menu (placeholder — to be populated in Phase 2 P2-5)

The full killshot menu will follow the H01 / H02 template: ranked by score = (kill_pr × info_weight) / (cost × time_penalty), with each killshot tagged to specific assumptions and failure modes per linter-design.md §4–5.

Anticipated highest-priority killshots:

  • Lit scan first. P2-1 (conjugate chemistry state-of-the-art) and P2-3 (commercial landscape) are the cheapest possible upstream moves. They answer whether the kidney-tropic delivery problem is being actively solved by competent groups (validation) or has been quietly stalled / abandoned (kill).
  • comp-009 URAT1 mRNA target site selection. If URAT1 mRNA has no accessible siRNA target sites with adequate structural exposure, the entire thesis collapses before delivery is even considered. Cheapest mechanistic killshot.
  • Pozdeutinurad Phase 3 outcome read (timing-dependent). If pozdeutinurad delivers ~2 mg/dL UA reduction with clean liver / renal safety at ~$100/month price, the niche for siRNA's distinctive value (durability + sequence-specificity + hormone-independence) narrows substantially. The 5–10 year horizon thesis weakens.
  • First-in-human kidney-tropic siRNA program failure (any indication). If Alport / PKD / kidney-fibrosis siRNA programs fail in Phase 1 over the next 3 years for delivery-chemistry reasons, the gout-specific extension becomes harder to justify on a partnership / spinout basis.

Pre-Committed Thresholds (placeholder — to be populated in Phase 2 P2-5)

To be defined when the killshot menu is populated. Anticipated structure follows H01: declared Alive / Killed / Pending thresholds for each load-bearing claim (target site accessibility, delivery chemistry maturation timeline, knockdown efficiency, competitive niche preservation), plus kill switches independent of the scientific thresholds (regulatory-precedent collapse, kidney-tropic delivery field-wide stagnation, pozdeutinurad-class small-molecule dominance).

Failure Modes Probed (placeholder — to be populated in Phase 2 P2-5)

To be populated. Anticipated relevant failure modes from linter-design.md §5: published-literature-gap (kidney-tropic delivery is field-wide pre-clinical), species-gap-translation (mouse kidney megalin vs. human), expression / localization mismatch, kinetics / concentration (knockdown depth at tolerable dose), dose-translation scaling, regulatory-precedent gap (first-in-class kidney-tropic siRNA biologic), competitive-displacement (small-molecule URAT1 class evolution).

Status

Stub. No killshot executed. No assumption stack pre-registered. Full hypothesis card is queued as Phase 2 P2-5 — see sirna-urat1-modality.md § Open Follow-Ups.

Survival count: 0.

Survival score: 0.0 (undefined until full card and first survived killshot).

Cross-References